These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 20646020)

  • 1. Cervical cancer: cytological cervical screening in Iceland and implications of HPV vaccines.
    Sigurdsson K
    Cytopathology; 2010 Aug; 21(4):213-22. PubMed ID: 20646020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
    Jenkins D
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
    Adams M; Jasani B; Fiander A
    Vaccine; 2007 Apr; 25(16):3007-13. PubMed ID: 17292517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of cervical cancer in rural China: evaluation of HPV vaccination and primary HPV screening strategies.
    Canfell K; Shi JF; Lew JB; Walker R; Zhao FH; Simonella L; Chen JF; Legood R; Smith MA; Nickson C; Qiao YL
    Vaccine; 2011 Mar; 29(13):2487-94. PubMed ID: 21211586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cervical screening in the era of HPV vaccination.
    Farnsworth A
    Cytopathology; 2010 Aug; 21(4):211-2. PubMed ID: 20646019
    [No Abstract]   [Full Text] [Related]  

  • 6. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening.
    Arbyn M; Dillner J
    J Clin Virol; 2007 Mar; 38(3):189-97. PubMed ID: 17258503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-grade cervical abnormalities and screening intervals in New South Wales, Australia.
    Schindeler S; Morrell S; Zuo Y; Baker D
    J Med Screen; 2008; 15(1):36-43. PubMed ID: 18416954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic HPV vaccination for women over 18 years of age.
    Adams M; Jasani B; Fiander A
    Vaccine; 2009 May; 27(25-26):3391-4. PubMed ID: 19200838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts.
    Wright TC; Bosch FX; Franco EL; Cuzick J; Schiller JT; Garnett GP; Meheus A
    Vaccine; 2006 Aug; 24 Suppl 3():S3/251-61. PubMed ID: 16950014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses.
    Barnabas RV; Laukkanen P; Koskela P; Kontula O; Lehtinen M; Garnett GP
    PLoS Med; 2006 May; 3(5):e138. PubMed ID: 16573364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Can human papillomavirus testing and vaccination prevent cervical cancer?].
    Lie AK; Bjørge T; Helland A; Hagen B; Skjeldestad FE; Hagmar B; Thoresen S
    Tidsskr Nor Laegeforen; 2001 Oct; 121(25):2947-51. PubMed ID: 11715778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology of human papillomavirus infection and cervical cancer and future perspectives in Hong Kong, Singapore and Taiwan.
    Tay SK; Ngan HY; Chu TY; Cheung AN; Tay EH
    Vaccine; 2008 Aug; 26 Suppl 12():M60-70. PubMed ID: 18945415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eligibility and willingness of young Icelandic women to participate in a HPV vaccination trial.
    Gudmundsdóttir T; Tryggvadóttir L; Allende M; Mast TC; Briem H; Sigurdsson K
    Acta Obstet Gynecol Scand; 2003 Apr; 82(4):345-50. PubMed ID: 12716319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating human papillomavirus vaccination in cervical cancer control programmes.
    Franco EL; Coutlée F; Ferenczy A
    Public Health Genomics; 2009; 12(5-6):352-61. PubMed ID: 19684447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cervical cancer prevention: the impact of HPV vaccination].
    Monsonégo J
    Gynecol Obstet Fertil; 2006 Mar; 34(3):189-201. PubMed ID: 16529969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
    Schwarz TF
    Adv Ther; 2009 Nov; 26(11):983-98. PubMed ID: 20024678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The current and future role of screening in the era of HPV vaccination.
    Myers E; Huh WK; Wright JD; Smith JS
    Gynecol Oncol; 2008 May; 109(2 Suppl):S31-9. PubMed ID: 18482556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium.
    Arbyn M; Benoy I; Simoens C; Bogers J; Beutels P; Depuydt C
    Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):321-30. PubMed ID: 19124515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing.
    Wheeler CM
    Nat Clin Pract Oncol; 2007 Apr; 4(4):224-35. PubMed ID: 17392713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Icelandic and Nordic cervical screening programs: trends in incidence and mortality rates through 1995.
    Sigurdsson K
    Acta Obstet Gynecol Scand; 1999 Jul; 78(6):478-85. PubMed ID: 10376856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.